论文部分内容阅读
罗伯特·努斯鲍姆表示,即使没有基因专利,公司也可以垄断遗传数据。今年6月,美国最高法院判决基因专利无效。然而,公司的知识产权声明仍会伤害病人。最高法院剥夺了Myriad Genetics公司所有的两个人类基因专利,这两个基因是BRCA1和BRCA2,和乳腺癌及卵巢癌相关。这一判决终结了Myriad Genetics公司在美国对这两个基因进行测试以寻找癌症相关突变的垄断。不过,现在Myriad采取了不同的策略来限制病人的遗传测试选择。公司建立了一个遗传变异数据库,收集那些接
Robert Nussbaum said companies can monopolize genetic data even without genetic patents. In June this year, the Supreme Court of the United States ruled that genetic patents were invalid. However, the company's intellectual property claims will still hurt the patient. The Supreme Court deprived Myriad Genetics of all two human genetic patents, the two genes BRCA1 and BRCA2, and breast and ovarian cancer. The verdict ended Myriad Genetics' two-gene test in the United States to find monopolies for cancer-related mutations. However, Myriad now has a different strategy to limit the patient's genetic testing choices. The company has created a database of genetic variations to collect those links